+
Site Tour
AMPLATZER™ TALISMAN™
PFO OCCLUDER
STRUCTURAL INTERVENTIONS

 

Effective patent foramen ovale (PFO) closure is made easier with the Amplatzer™ Talisman™ PFO Occluder.1 For patients who have experienced a PFO-associated stroke, clinical trials have shown that they can benefit from PFO closure.2–4 This minimally invasive procedure significantly

SWITCH TO THE REFERRAL VIEW    For more information specific to neurology regarding PFO closure 

ADVANCING THE GOLD STANDARD IN PFO CLOSURE

For decades, interventional cardiologists have trusted the Amplatzer™ PFO Occluder for ease of use, safety, and excellent clinical outcomes.2 With our latest addition, the Amplatzer™ Talisman™ PFO Occlusion System, the easy to use just got easier:

  • The occluder comes assembled and ready to use, streamlining preparation and enhancing the user experience
  • We have re-engineered the 30 mm size with a smaller left atrial disc to better avoid interference with surrounding structures

Often Imitated, Never Matched

Unique design features set the Amplatzer™ Talisman™ PFO Occluder apart from the rest.
 

*Only the 18 mm size is not asymmetric
Effective closure


Minimizing Complexity in PFO Closure

SIMPLIFIED PREPARATION

Occuluder comes assembled to the flexible Trevisio™ delivery cable, ready to use


RECAPTURABLE &
REPOSITIONABLE

Self-expanding discs align to the PFO without an additional “locking” step and can be adjusted for ideal placement

LOW PROFILE DELIVERY

8 F and 9 F sheaths enable treatment of patients with smaller vasculature


NEW VERSION AVAILABLE
GET THE AMPLATZER™ PORTFOLIO APP

The Amplatzer™ Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.

Connext
Live

Bringing together the cardiovascular and stroke prevention community for live virtual events with the most respected KOLs. 

Find out more

 

TV

References
  1. Data on file at Abbott.
  2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022–1032. doi.org/10.1056/NEJMoa1610057.
  3. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033–1042. doi.org/10.1056/NEJMoa1707404.
  4. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011–1021 and supplementary appendix. doi.org/10.1056/NEJMoa1705915.
  5. Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876–885. doi.org/10.1212/WNL.0000000000009443.

© Abbott 2024. All rights reserved. 9-EH-5-14385-01 04-2024 REV A

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline